SRC
TMO icon

Stone Run Capital’s Thermo Fisher Scientific TMO Stock Holding History

Stone Run Capital’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$6.31M Buy
13,012
+1,540
+13% +$717K 2.49% 15
2025
Q2 		$4.65M Sell
11,472
-260
-2% -$109K 1.86% 25
2025
Q1 		$5.84M Sell
11,732
-1,030
-8% -$558K 2.46% 17
2024
Q4 		$6.64M Sell
12,762
-570
-4% -$313K 2.61% 15
2024
Q3 		$8.25M Buy
13,332
+25
+0.2% +$14.8K 3.07% 10
2024
Q2 		$7.36M Sell
13,307
-500
-4% -$286K 2.94% 10
2024
Q1 		$8.02M Sell
13,807
-500
-3% -$281K 3.07% 11
2023
Q4 		$7.59M Sell
14,307
-710
-5% -$344K 3.25% 11
2023
Q3 		$7.6M Buy
15,017
+25
+0.2% +$13.3K 3.73% 8
2023
Q2 		$7.82M Buy
14,992
+25
+0.2% +$13.5K 3.47% 10
2023
Q1 		$8.63M Sell
14,967
-600
-4% -$338K 4.12% 4
2022
Q4 		$8.57M Sell
15,567
-900
-5% -$477K 4.33% 4
2022
Q3 		$8.35M Buy
16,467
+5
+0% +$2.8K 4.5% 3
2022
Q2 		$8.94M Sell
16,462
-1,335
-8% -$735K 4.5% 3
2022
Q1 		$10.5M Sell
17,797
-558
-3% -$321K 3.88% 5
2021
Q4 		$12.2M Sell
18,355
-885
-5% -$553K 3.96% 5
2021
Q3 		$11M Buy
19,240
+545
+3% +$299K 3.77% 6
2021
Q2 		$9.43M Buy
18,695
+127
+0.7% +$59.9K 3.33% 9
2021
Q1 		$8.47M Sell
18,568
-1,100
-6% -$525K 3.24% 9
2020
Q4 		$9.16M Sell
19,668
-587
-3% -$275K 3.64% 5
2020
Q3 		$8.94M Buy
20,255
+165
+0.8% +$68.2K 4.09% 3
2020
Q2 		$7.28M Buy
20,090
+170
+0.9% +$57K 3.6% 6
2020
Q1 		$5.65M Sell
19,920
-3,090
-13% -$974K 3.24% 10
2019
Q4 		$7.47M Sell
23,010
-960
-4% -$291K 3.32% 9
2019
Q3 		$6.98M Buy
23,970
+1,000
+4% +$286K 3.33% 9
2019
Q2 		$6.75M Buy
22,970
+150
+0.7% +$41.3K 3.08% 10
2019
Q1 		$6.25M Hold
22,820
– – 3.07% 12
2018
Q4 		$5.11M Sell
22,820
-1,450
-6% -$340K 3.18% 10
2018
Q3 		$5.92M Sell
24,270
-50
-0.2% -$11.5K 2.72% 12
2018
Q2 		$5.04M Buy
24,320
+200
+0.8% +$42.5K 2.66% 14
2018
Q1 		$4.98M Sell
24,120
-75
-0.3% -$15.7K 2.61% 14
2017
Q4 		$4.59M Sell
24,195
-50
-0.2% -$9.58K 2.36% 15
2017
Q3 		$4.59M Buy
24,245
+125
+0.5% +$22.6K 2.36% 17
2017
Q2 		$4.21M Hold
24,120
– – 2.32% 17
2017
Q1 		$3.71M Sell
24,120
-100
-0.4% -$15.3K 2.23% 18
2016
Q4 		$3.42M Buy
24,220
+100
+0.4% +$14.7K 2.22% 22
2016
Q3 		$3.84M Hold
24,120
– – 2.39% 18
2016
Q2 		$3.56M Hold
24,120
– – 2.32% 15
2016
Q1 		$3.42M Sell
24,120
-1,200
-5% -$161K 2.2% 18
2015
Q4 		$3.59M Hold
25,320
– – 2.5% 10
2015
Q3 		$3.1M Sell
25,320
-550
-2% -$71.7K 2.46% 13
2015
Q2 		$3.36M Hold
25,870
– – 2.2% 19
2015
Q1 		$3.48M Sell
25,870
-250
-1% -$32.2K 2.24% 16
2014
Q4 		$3.18M Hold
26,120
– – 2.18% 11
2014
Q3 		$3.18M Hold
26,120
– – 2.25% 11
2014
Q2 		$3.08M Sell
26,120
-1,000
-4% -$118K 2.02% 17
2014
Q1 		$3.26M Sell
27,120
-6,600
-20% -$785K 2.37% 12
2013
Q4 		$3.75M Hold
33,720
– – 2.65% 8
2013
Q3 		$3.11M Hold
33,720
– – 2.53% 9
2013
Q2 		$2.85M Buy
+33,720
New +$2.81M 2.75% 10

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Stone Run Capital's TMO Position: Q3 2025 in Review

Stone Run Capital increased its Thermo Fisher Scientific (TMO) stake by 13% in Q3 2025, buying an estimated $717K and bringing the position to 13,012 shares worth $6.31M. The position accounts for 2.49% of the portfolio, ranked #15.

Stone Run Capital first reported a position in TMO in Q2 2013 and has held it in 50 quarters since. The position peaked at $12.2M in Q4 2021. 2,508 funds tracked by Wall St. Rank hold TMO as of Q3 2025.

  • Stone Run Capital held 13,012 shares of Thermo Fisher Scientific worth $6.31M as of Q3 2025.
  • Stone Run Capital bought 1,540 Thermo Fisher Scientific shares in Q3 2025, an estimated $717K.
  • Thermo Fisher Scientific made up 2.49% of Stone Run Capital's portfolio in Q3 2025, its #15 holding.
  • Stone Run Capital first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 50 quarters since.
  • Stone Run Capital's Thermo Fisher Scientific position peaked at $12.2M in Q4 2021.
  • 2,508 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2025.

Based on Stone Run Capital's 13F filing for Q3 2025, filed 14 Nov 2025.